Figure 1: Myosin (Myo) IIA and myosin IIB localize to apical epithelial junctions. Figure 2: Differential regulation of myosin IIA and myosin IIB localization at apical junctions. Figure 4: Homophilic ...

The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...

With intensifying global warming and climate change, drought has become a major threat to global agriculture, impacting crop yields and food security. To survive such adverse events, plants have ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

A decade ago, when Courtney Miller of Scripps Research in Florida found that blocking a specific protein can interrupt methamphetamine addiction in mice, it was difficult to imagine drugs targeting ...

Temperature is a key physiological factor that determines the speed of immune reactions. While this may seem obvious, it has remained largely unexplored at the single-cell level-until now. Stefan ...

In its early stages, Alzheimer disease is increasingly recognized as a disease of synapses, those key mediators of memory storage in the brain. Enhancing synaptic function, therefore, might be a ...

Boron, though required only in minimal amounts, is vital for plant development. It strengthens cell walls and supports the growth of roots and shoots. Normally, boron, in the form of boric acid, is ...

JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding ...